Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metronidazole + amoxicillin + omeprazole
- Development stage
- Unknown
- Lead developer
- Shaheed Zulfiqar Ali Bhutto Medical University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This drug is a triple therapy regimen consisting of two antibiotics, metronidazole and amoxicillin, and a proton pump inhibitor, omeprazole. It is used for the eradication of *Helicobacter pylori* infection, particularly in patients with gastritis or peptic ulcer disease. Metronidazole is a nitroimidazole that disrupts bacterial DNA, amoxicillin is a beta-lactam that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, and omeprazole reduces gastric acid secretion by inhibiting the H+/K+-ATPase pump in parietal cells. This specific combination was evaluated by the Shaheed Zulfiqar Ali Bhutto Medical University in a pediatric population in Pakistan to compare its efficacy against clarithromycin-based regimens.
- Other names
- Amoxicillin + Metronidazole + OmeprazoleAMO + MET + PPIMetronidazole + Amoxicillin + Omeprazole
02
Targets
PBP (Penicillin-binding protein family)ATP4A (Potassium–transporting ATPase alpha chain 1)DNA
Beyond the preview
Go deeper on metronidazole + amoxicillin + omeprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metronidazole + amoxicillin + omeprazole.